Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication
|
|
- Kory Reeves
- 5 years ago
- Views:
Transcription
1 786926TAK / Therapeutic Advances in Cardiovascular DiseaseR Deev, I Plaksa research-article2018 Therapeutic Advances in Cardiovascular Disease Original Research Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication Roman Deev, Igor Plaksa, Ilia Bozo, Nina Mzhavanadze, Igor Suchkov, Yuriy Chervyakov, Ilia Staroverov, Roman Kalinin and Artur Isaev Ther Adv Cardiovasc Dis 2018, Vol. 12(9) DOI: The Author(s), Reprints and permissions: journalspermissions.nav Abstract Background: The effective treatment of chronic lower limb ischemia is one of the most challenging issues confronting vascular surgeons. Current pharmacological therapies play an auxiliary role and cannot prevent disease progression, and new treatment methods are needed. In 2011, a plasmid VEGF65-gene therapy drug was approved in Russia for the treatment of chronic lower limb ischemia (ClinicalTrials.gov identifier: NCT ). The objective of this follow-up study was to evaluate the long-term safety and efficacy of gene therapy in patients with limb ischemia of atherosclerotic genesis. Aims: To evaluate the long-term safety and efficacy of the therapeutic angiogenesis, 36 patients in the treatment group (pl-vegf165) and 12 patients in the control group participated in a 5-year follow-up study. Planned examinations were carried out annually for 5 years after pl-vegf165 administration. Results: Differences in the frequency of major cardiovascular events (pl-vegf165 5/36 versus control 2/12; p = 0.85), malignancies (pl-vegf165 1/36 versus control 0/12; p = 0.38) and impaired vision (there was none in either group) over the 5-year follow-up period did not achieve statistical significance. The target limb salvage was 95% (n = 36) and 67% (n = 12) in the pl-vegf165 and control groups, respectively. The pain-free walking distance value increased by 288% from ± 16.5 m to 384 ± 39 m in the treatment group by the end of the fifth year, with a peak of ± 86.1 m achieved by the end of the third year. The anklebrachial index (ABI) increased from 0.47 ± 0.01 to 0.56 ± 0.02 by the end of the first year, with a subsequent slight decrease to 0.51 ± 0.02 by the fifth year. The maximum increment of transcutaneous oximetry test (tcoo 2 ) by 36%, from 66.6 ± 3.7 mm Hg to 90.7 ± 4.9 mm Hg, was observed by the end of the second year. Conclusion: The therapeutic effect of angiogenesis induction by gene therapy persists for 5 years. Keywords: therapeutic angiogenesis, gene therapy, VEGF165, intermittent claudication Received: 17 January 2018; revised manuscript accepted: 4 May Introduction Despite significant technological advances in the surgical treatment of patients with atherosclerotic lower limb vascular disease, the amputation rate ranges from 188 to 263 per 100,000 population per year in developed countries. 1 Based on the data from the Russian Consensus, critical lower limb ischemia (CLI) is a significant cause of amputation in 30,000 40,000 people in the Russian Federation annually. 2 At the same time, the results of large pharmacoeconomic studies showed that increased costs for medical care of patients with peripheral arterial disease (PAD) no longer reduce these numbers. 3 This is the result of achieving the limit of surgical care capabilities and the moderate ability of most therapeutic agents to correct ischemia. This was a prerequisite for conducting clinical trials in the field of Correspondence to: Igor Plaksa Human Stem Cells Institute, Moscow, Russia Moscow City Oncology Hospital No 62, Moscow, Russia i.plaksa2014@yandex.ru Roman Deev Human Stem Cells Institute, Moscow, Russia Ryazan I.P. Pavlov State Medical University, Ryazan, Russia Ilia Bozo Human Stem Cells Institute, Moscow, Russia A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia Nina Mzhavanadze Igor Suchkov Roman Kalinin Ryazan I.P. Pavlov State Medical University, Ryazan, Russia Yuriy Chervyakov Ilia Staroverov Yaroslavl Regional Clinical Hospital, Yaroslavl, Russia Artur Isaev Human Stem Cells Institute, Moscow, Russia 237
2 Therapeutic Advances in Cardiovascular Disease 12(9) gene therapy. 4 5 Numerous publications over the last 20 years have shown that the use of gene therapy constructions with the VEGF gene as an inductor of angiogenesis is well-tolerated and does not have a systemic effect. 6 Unfortunately, most of the phase II III registration studies that aimed to evaluate the potential of therapeutic angiogenesis as a remedy to save a limb in patients with terminal disease failed. 7 The knowledge accumulated in the field of gene therapy of PAD led to the understanding that its use is most effective at the stage of intermittent claudication, before the development of necrotic ulcerations, since the presence of irreversible tissue changes creates unfavorable conditions for gene-mediated induction of angiogenesis. This determined a change in the approach to conducting clinical trials in this field as well as inclusion criteria and efficacy endpoints. 8 The paradigm change in the field of PAD gene therapy resulted in the approval of the world s first gene therapy drug for the treatment of patients in these categories, with the active ingredient pl- VEGF165 (ClinicalTrials.gov identifier: NCT ). The objective of this followup study was to evaluate the long-term safety and efficacy of gene therapy in patients with CLI Materials and methods Rationale for the clinical study Preclinical studies of general toxicity (acute, subacute, chronic, and local irritation) and specific toxicity (allergenicity, reproductive and immune toxicity, mutagenicity and carcinogenicity), as well as the detection of specific drug activity, was carried out at the Russian State federal institution the Institute of Toxicology of Federal Medical Biological Agency of Russia, Saint-Petersburg (2008). The tolerability, feasibility, and shortterm efficacy of the study drug were then evaluated in a phase I to IIa multicenter randomized trial that was conducted in 2010 and which enrolled 45 patients. The Federal Service on Surveillance of the Ministry Healthcare and Social Development of the Russian Federation granted approval to conduct a phase IIb to III study (approval notice no. 177, 21 April 2010). The study protocol was approved by the National Ethics Committee (protocol no. 62 from 7 April 2010); local ethics committees have also granted their approval to conduct the study. All phases of clinical trials were conducted according to the Declaration of Helsinki of the World Medical Association s Recommendations guiding physicians in biomedical research involving human subjects (1964, 2000), Rules of good clinical practice in the Russian Federation, OST , ICH GCP rules, and valid regulatory requirements. The follow-up study protocol was also approved by the local ethics committees of Ryazan State I.P. Pavlov Medical University (protocol no. 4 from 20 October 2011) and Yaroslavl State Medical Academy (protocol no. 30 from 7 November 2011). Study population Having completed the phase IIb/III registration study, 48 of the patients (12 patients in the control group and 36 in the pl-vegf165 group) gave their consent to participate in a 5-year follow-up study. At baseline, all patients were diagnosed with intermittent claudication and/or CLI of atherosclerotic genesis without necrotic changes that correlated with stage II III under the Fontaine classification as modified by A.V. Pokrovsky [a pain-free walking distance (PWD) of not more than 1000 m and no necrotic ulcerations in limb soft tissues]. None of the patients with stage III disease could have revascularization surgery because of the lesion extent and the severity of structural changes in the vessel wall. Depending upon the anatomy and involvement in a pathological process, the patients had atherosclerotic lesions of the following patterns: proximal occlusion of the femoral artery and patency of the iliac segment; multilevel occlusion in the superficial femoral, popliteal and tibial arteries; distal occlusion or hemodynamically significant stenosis in tibial arteries. Description of pl-vegf165 The study drug is an original gene construction containing a supercoiled plasmid DNA (1.2 mg)- encoding pl-vegf165 as the active substance and is now marketed as Neovasculgen. 9 pl- VEGF165 was used only in the phase IIb/III registration clinical study; no re-administration of the drug was done during the subsequent follow up. The drug was kept as a lyophilizate dissolved in 2 ml of water for injection immediately before administration. The solution was given as 5 10 intramuscular injections into the calf muscles twice, 1.2 mg at an interval of 14 days (a total dose of 2.4 mg)
3 R Deev, I Plaksa et al. Figure 1. Design and time points of the follow-up study. ABI, ankle-brachial index; PWD, pain-free walking distance; TcPO2, Transcutaneous Oximetry Test. Design and time points of the follow-up study The phase IIb/III registration clinical study was designed as a randomized, open, comparative study with a 6-month duration. A total of 100 patients with CLI were randomized into the control group (n = 25), who received standard conservative therapy without cilostazol and prostaglandins, and the treatment group (n = 75), who received standard conservative treatment and pl-vegf165. Control examination time points in the follow-up period after the end of the clinical trial were 1, 2, 3, 4 and 5 years after pl-vegf165 administration (Figure 1). Over this period of time, all patients had standard therapy including 75 mg of acetylsalicylic acid (aspirin)/clopidogrel, statins in individual doses in order to reduce the risk of cardiovascular complications, and pentoxifylline without prostaglandins and prostacyclins. Every patient was informed about the study goals and objectives and the potential benefits and risks of participating in it prior to inclusion in the follow-up study. All the patients signed the voluntary informed consent form. The follow-up study protocol was approved by a local Ethics Committee at every study site (ClinicalTrials.gov identifier: NCT ). Safety assessment Adverse events (AEs) and serious adverse events were recorded over 5 years of the follow-up study to evaluate drug safety. During screening, the patients had ECG, blood hematology and biochemistry, a coagulation panel and urinalysis performed in order to detect any concomitant and underlying disorders. Fluorography, abdominal ultrasound, gastroscopy and colonoscopy were performed if required in order to rule out malignancies and other complications. Efficacy assessment The same parameters that were used as efficacy endpoints in the registration clinical study were evaluated during control examinations. A PWD value was used as the primary efficacy endpoint. It was measured on a treadmill with an elevation angle of 0 and a speed of 1 km/h; the walking distance was registered from the start to pain in the limb muscle (evidence grade B according to the TASC-II). The disease was staged under the Fontaine classification modified by A.V. Pokrovsky that is widely applied by Russian and Ukrainian vascular surgeons. According to this classification, a PWD of more than 200 m indicates stage IIA disease and of less than 200 m but more than 50 m indicates stage IIB disease. The disease is rated as stage III when the PWD is less than 50 m and/or there is resting pain without any ischemic tissue changes (trophic ulcer and/or necrosis). TcPO2 of the involved limb and the ABI were used as secondary efficacy endpoints (Table 1). Mortality and 239
4 Therapeutic Advances in Cardiovascular Disease 12(9) Table 1. Baseline characteristics of 5-year follow-up study patients. Parameter Control group (standard therapy) (n = 12) Treatment group (pl-vegf165) (n = 36) Statistical significance of the differences between groups Average age 64.6 ± ± 9.4 (t test) p = Gender distribution, n (%) M 7 (58.0) 25 (69.4) Chi-square F 5 (42.0) 11 (30.6) Yates corrected Chisquare Smoking Yes 4 (33.4) 10 (27.7) (Chi-square) p = No 8 (66.6) 26 (72.3) (Chi-square) p = Diabetes mellitus Type I Type II 1 (8.3) 4 (11.1) (Chi-square) p = Severity of CLI, n % IIa 0 (0.0) 2 (5.6) (Chi-square) p = IIb 9 (75.0) 21 (58.3) (Chi-square) p = III 3 (25.0) 13 (36.1) (Chi-square) p = Level of occlusion, n (%) Proximal 2 (16.0) 10 (27.8) (Chi-square) p = Distal 6 (50.0) 15 (41.6) (Chi-square) p = Multilevel disease 4 (34.0) 11 (30.6) (Chi-square) p = PWD, m ± ± 8.1 (Mann Whitney U test) ABI, U 0.47 ± ± 0.03 (Mann Whitney U test) TcPO2, mmhg 66.7 ± ± 3.9 (Mann Whitney U test) ABI, ankle-brachial index; CLI, chronic limb ischemia; PWD, pain-free walking distance; TcPO2, transcutaneous oxygen pressure. amputation rates by the end of the 5-year followup study were also calculated in both groups. Statistical data processing A sample size of 28 patients in each group in the phase IIb/III registration study was estimated to detect a 0.75 standardized difference (80% power, p = 0.05), assuming the target difference and standard deviation for PWD to be 75 m and 100 m, respectively. We decided to use a 3:1 test/ control group ratio in order to make the test group sample more representative. 9 The power analysis for the subsequent follow up was not made 240
5 R Deev, I Plaksa et al. Table 2. Mortality and serious adverse events in the treatment and control study groups during the 5-year follow-up study. Parameter Control (n = 12) pl-vegf165 (n = 36) Statistical significance of the differences between groups (Chi-square) Number of amputations 4 (33%) 2 (5%) p = 0.008* AMI 1 (8.3%) 3 (8.3%) p = ACVE 1 (8.3%) 2 (5.5%) p = Cancer 0 1 (2.7%) p = Mortality 2 (16%) 6 (16.6%) p = ACVE, acute cerebrovascular event; AMI, acute myocardial infarction. * p < because patients after the registration trial were included freely on the basis of their own desire to participate, depending on their capabilities. Absolute values of the efficacy endpoints (PWD, ABI, and TcPO2) complied with a non-normal distribution. Therefore, nonparametric methods (a Mann Whitney U test and a Wilcoxon signedrank test) were used for the statistical analysis; additionally, a Chi-squared test was used to evaluate the significance of differences in the event frequencies in pl-vegf165 and control groups. Results Baseline characteristics of patients in the follow-up study A comparative analysis of the baseline characteristics showed that the groups were comparable for gender composition, age and primary and secondary efficacy endpoint values. Baseline PWD values were comparable between both groups at ± 16.5 m and 99.3 ± 8.4 m (p = 0.672) in the pl-vegf165 and control groups, respectively. There were no significant differences in the structure of patient distribution for disease stages and level of lower limb vascular lesions; patients with stage IIB disease and distal lesions prevailed in both groups (Table 1). Five patients from the treatment group and one from the control group had resting pains of various intensities at the beginning of the study. Safety assessment No AEs related to the use of pl-vegf165 were recorded. Neither tumor formation, nor impaired vision nor any other pathology that could indirectly indicate angiogenic therapy complications were detected at any time points during the follow-up study. The mortality rate over the entire follow-up period was 16.6%, 6/36 and 2/12 in the pl-vegf165 and control groups, respectively. Two patients from the pl-vegf165 group (n = 36) and four patients from the control group (n = 12) underwent amputations of the lower limb as a result of ischemia progression and revascularization surgery infeasibility. Thus, the amputationfree survival was 95% and 67%, respectively (Table 2). Two patients from the control group and five patients from the pl-vegf165 group had cardiovascular complications as a result of a generalized atherosclerotic lesion of the vessel wall. In the third year of the follow-up study, metastatic renal cancer was diagnosed in one patient from the treatment group, which was fatal. Efficacy assessment The maximum increase of PWD by 288% from ± 16.5 m to ± 86.1 m (p = 0.000) was observed in the treatment group by the end of the third follow-up year. In general, these values stabilized in the subsequent 2 years; there was only a slight decrease by 26.5 m to ± 39.6 m by the end of the fifth follow-up year. The PWD values were almost unchanged in the control group (Table 3). The most evident increase of PWD in the pl- VEGF165 group was observed in patients with stage III disease (n = 13). The value increased from 24.3 ± 5.3 m to 378 ± 73.1 m by the end of the 5-year follow-up period (p = ). At 241
6 Therapeutic Advances in Cardiovascular Disease 12(9) Table 3. Primary and secondary efficacy endpoints in the 5-year follow-up study. Parameter Statistical significance of in-group differences, M ± m Baseline 6 months Year 1 Year 2 30/10 Year 3 28/8 Year 4 26/5 Year 5 22/3 Treatment group (n = 36) PWD ± ± ± ± ± ± ± 39.6 p = p = p = p = p = p = p* = p* = p* = p* = p* = ABI 0.47 ± ± ± ± ± ± ± 0.02 p = p = p = p = p = p = p* = p* = p* = p* = p* = TcPO ± ± ± ± ± ± ± 1.8 p = p = p = p = p = p = p* = p* = p* = p* = p* = Control group (n = 12) PWD 99.3 ± ± ± ± ± ± ± 4.6 p = p = p = p = p = p = p* = p* = p* = p* = p* = ABI 0.39 ± ± ± ± ± ± ± 0.02 p = p = p = p = p = p = p* = p* = p* = p* = p* =
7 R Deev, I Plaksa et al. Table 3. (Continued) Parameter Statistical significance of in-group differences, M ± m Baseline 6 months Year 1 Year 2 30/10 Year 3 28/8 Year 4 26/5 Year 5 22/3 TcPO ± ± ± ± ± ± ± 1.2 p = p = p = p = p = p = p* = p* = p* = p* = p* = Significance of differences between groups, p value PWD () p = p = p = p = p = p = p = ABI () p = p = p = p = p = p = p = TcPO2 () p = p = p = p = p = p = p = ABI, ankle-brachial index; CLI, chronic limb ischemia; PWD, pain-free walking distance; TcPO2, transcutaneous oxygen pressure; p *, compared with baseline
8 Therapeutic Advances in Cardiovascular Disease 12(9) the same time, unlike the dynamics of mean values in the treatment group in general, the maximum incremental value was observed only by the end of the fifth follow-up year. Depending upon the level of lesion, patients with distal and multilevel disease had the highest incremental value, from 89 ± 20.9 to 510 ± 90.7 (p = ) and from ± 43.5 to ± 49.8 (p = 0.001), respectively. Positive changes in the PWD, that is from ± 19.7 to ± 57.4 (p = 0.012), were less evident for proximal lesions. No selective analysis in dependence upon a disease stage and a level of occlusion was performed in the control group because of the small sample size (Table 3). The mean ABI value increased from 0.47 ± 0.01 to 0.51 ± 0.02 (p = 0.049) in the treatment group over the 5-year follow-up period, with a peak of 0.56 ± 0.02 achieved by the end of the first year of follow-up (p = 0.028). Macrohemodynamic parameters correlated with TcPO2 values that increased by 27% from 66.7 ± 3.8 mmhg to 84.1 ± 1.8 mmhg (p = 0.021), with a peak at 90.6 ± 0.4 mmhg in the second year of follow up. In the control group, the ABI slightly increased from 0.39 ± 0.03 to 0.42 ± 0.02 (p = 0.320), with subtle fluctuations over the entire 5-year follow-up period. TcPO2 increased by 26% from 64.2 ± 3.4 to 81 ± 2.0 mmhg by the end of the second year of follow up, and then there was a moderate gradual decrease by 7.4% by the end of the fifth year (Table 3). Discussion The objective of the 5-year follow-up study was to evaluate the long-term tolerability and efficacy of angiogenesis induction with gene therapy in patients with CLI. The results demonstrated that the use of pl-vegf165 was not followed by the increased frequency of cardiovascular complications, malignancies or impaired vision. This gives evidence that the drug is a local angiogenesis inductor without a systemic effect. To date, this is one of the most prolonged studies aiming to evaluate the long-term safety and efficacy of gene therapy. Studies performed by other teams also demonstrate that the safety profile of gene therapy with VEGF is acceptable. An 8-year follow-up study involving patients with coronary artery disease after administration of VEGF-Adv (n = 37) and pl-vegf (n = 28) demonstrated that the use of gene therapy to induce angiogenesis did not result in increased frequency of tumor formation or cardiovascular complications compared with a placebo (n = 38). 12 An intracoronary infusion of VEGF-Adv caused only transitory increased lactate dehydrogenase (LDHG) levels in several recipients. The results of the 10-year follow-up study of patients with CLI who had intramuscular administration of VEGF-Adv (n = 18) and pl-vegf (n = 17) within the placebocontrolled phase II study also demonstrated the tolerability of this treatment approach. 13 None of the follow-up studies revealed increased systemic VEGF levels or increased frequency of diabetic retinopathy after gene therapeutic constructions were administered that could indirectly indicate a systemic effect. Thus, to date there is no evidence that VEGF-based gene therapy is capable of inducing the growth of blood vessels at a considerable distance from an injection site. This is consistent with our concept of pl-vegf165 as a local inductor of angiogenesis. The registered clinical study aimed to evaluate the possible use of gene therapy to prevent ischemia progression to necrotic ulcerations. Therefore, target limb salvage was not used as the efficacy endpoint because patients in these categories do not have an immediate threat of losing their limbs in the near future. 9,10 However, the 5-year follow-up study demonstrated that the long-term amputation rate in the pl-vegf165 group was significantly lower (p = 0.008). The results that were obtained cannot be extrapolated to the whole population of patients with CLI because of the small sample size. However, they confirm our working hypothesis that the use of gene therapy before irreversible structural changes develop in tissues can reduce the risk of ischemia progression and thereby decrease the likelihood of amputation in the future. To date, numerous data have been obtained in the field of gene therapy in cardiovascular diseases that indicate that use of gene therapy constructions with the gene VEGF is an effective tool to correct lower limb ischemia. However, the attitude of the vascular community is generally skeptical. This is largely because since work began in this field, gene therapy has been considered primarily as a tool to save a limb in patients with CLI over a long period of time. This is the basis of most studies, with participation of patients with a terminal form (stage) of the disease and the use of strict efficacy endpoints. This approach is 244
9 R Deev, I Plaksa et al. caused by ethical aspects because of traditional alertness about the safety of VEGF gene-based constructions, and by the availability of a large arsenal of surgical techniques with definite efficacy that in general determined the enrollment of patients who are poor surgical candidates. The results of our studies show that early forms of CLI before the development of apparent and irreversible trophic changes, such as necrosis and ulcers, are a therapeutic window for the use of pl- VEGF165. The induction of angiogenesis in this period can significantly improve the functional state of patients with PAD and prevent the progression of ischemia. The main limitation of this study was its openlabel nature, suggesting a high risk of detection bias for subjective outcomes like PWD. Also, the power analysis was initially made only for the phase IIb/III registration study because subsequent participation of patients in the follow-up study was based on their own desire, depending on their capabilities. Although the open-label use of study drugs is a limitation, this study was randomized and involved three centers, and patient enrollment decisions were made independently by a team of vascular surgeons and radiologists on the basis of angiographic results, disease history, previous procedures and concomitant pathology. Additionally, the prolonged stable therapeutic effect of the gene therapy during the 5-year follow-up period is evidence that it is not connected with a placebo effect. Conclusion The use of pl-vegf165 demonstrates good tolerability and is not followed by tumor formation, cardiovascular complications or impaired vision. When pl-vegf165 is used before necrotic-ulcerative changes develop in patients with CLI, its therapeutic effect persists for at least 5 years. Acknowledgements The authors would like to thank the clinical investigators for their contribution in conducting this trial and participating in the studies. Ethics statement The study was conducted according to the Declaration of Helsinki of the World Medical Association Recommendations guiding physicians in biomedical research involving human subjects (1964, 2000), Rules of good clinical practice in the Russian Federation, OST , ICH GCP rules and valid regulatory requirements. Funding This study was funded by the PJSC Human Stem Cells Institute (Moscow, Russia). Conflict of interest statement The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: A.A. Isaev, I. Ya. Bozo, R.V. Deev and I.L. Plaksa are employees of the PJSC Human Stem Cells Institute. A.A. Isaev is a shareholder of the PJSC Human Stem Cells Institute. ORCID id Igor Plaksa References 1. Goodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg 2009; 50: Bokeriia LA, Pokrovskiĭ AV, Belov UV, et al. National guidelines for management of patients with pathology of lower limb arteries. Angiology Vasc Surg 2013; 19: Goodney PP, Travis LL, Brooke BS, et al. Relationship between regional spending on vascular care and amputation rate. JAMA Surg 2014; 149: Morishita R, Nakamura S, Hayashi S, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999; 33: Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16: Gupta R, Tongers J and Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009; 105: Cooke JP and Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res 2015; 116: Ylä-Herttuala S, Bridges C, Katz MG, et al. Angiogenic gene therapy in cardiovascular diseases: dream or vision? Eur Heart J 2017; 38:
10 Therapeutic Advances in Cardiovascular Disease 12(9) Visit SAGE journals online SAGE journals 9. Deev R, Bozo I, Mzhavanadze N, et al. pcmv- VEGF165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia. J Cardiovasc Pharmacol Ther 2015; 20: Deev R, Plaksa I, Bozo I, et al. Results of an international postmarketing surveillance study of pl-vegf165 safety and efficacy in 210 patients with peripheral arterial disease. Am J Cardiovasc Drugs. Epub ahead of print DOI: / s Yudin M, Plaksa I, Mzhavanadze N, et al. Estimation of systemic distribution and angiogenic effect of pl-vegf165 in the model of limb ischemia. Circulation Pathology and Cardiac Surgery 2015; 19: Hedman M, Muona K, Hedman A, et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009; 16: Muona K, Mäkinen K, Hedman M, et al. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther 2012; 19:
Results of an International Postmarketing Surveillance Study of pl-vegf165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease
Am J Cardiovasc Drugs (2017) 17:235 242 DOI 10.1007/s40256-016-0210-3 ORIGINAL RESEARCH ARTICLE Results of an International Postmarketing Surveillance Study of pl-vegf165 Safety and Efficacy in 210 Patients
More informationImaging Strategy For Claudication
Who are the Debators? Imaging Strategy For Claudication Duplex Ultrasound Alone is Adequate to Select Patients for Endovascular Intervention - Pro: Dennis Bandyk MD No Disclosures PRO - Vascular Surgeon
More informationJohn E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationNo option-patients : Is angiogenesis with gene or cell therapy still an option?
No option-patients : Is angiogenesis with gene or cell therapy still an option? Professor Sigrid Nikol Clinical and Interventional Angiology Asklepios-Klinik St. Georg Hamburg, Germany Angiogenic gene
More informationMaximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia Traci A. Kimball, MD Department of Surgery Grand Rounds Septemember 13, 2010 Overview Defining Critical Limb Ischemia Epidemiology
More informationDue to Perimed s commitment to continuous improvement of our products, all specifications are subject to change without notice.
A summary Disclaimer The information contained in this document is intended to provide general information only. It is not intended to be, nor does it constitute, medical advice. Under no circumstances
More informationPractical Point in Holistic Diabetic Foot Care 3 March 2016
Diabetic Foot Ulcer : Vascular Management Practical Point in Holistic Diabetic Foot Care 3 March 2016 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai
More informationTreatment Strategies For Patients with Peripheral Artery Disease
Treatment Strategies For Patients with Peripheral Artery Disease Presented by Schuyler Jones, MD Duke University Medical Center & Duke Clinical Research Institute AHRQ Comparative Effectiveness Review
More information3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
More informationThe Struggle to Manage Stroke, Aneurysm and PAD
The Struggle to Manage Stroke, Aneurysm and PAD In this article, Dr. Salvian examines the management of peripheral arterial disease, aortic aneurysmal disease and cerebrovascular disease from symptomatology
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationJohn E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationPAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014 Van Crisco, MD, FACC, FSCAI First Coast Heart and Vascular Center, PLLC Jacksonville, FL 678-313-6695 Conflict of Interest Bayer Healthcare
More informationPATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE
PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE Disclosure Speaker name: DR. Manar Trab I have the following potential
More informationUtility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis
2016 Annals of Vascular Diseases doi:10.3400/avd.oa.16-00074 Original Article Utility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis Kazuo Tsuyuki, CVT, PhD, 1 Kenji Kohno, PhD,
More informationPractical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
More informationCurrent Vascular and Endovascular Management in Diabetic Vasculopathy
Current Vascular and Endovascular Management in Diabetic Vasculopathy Yang-Jin Park Associate professor Vascular Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Peripheral artery
More informationUSWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential
USWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential MEASURE STEWARD: The US Wound Registry [Note: This measure
More informationIntroduction. Risk factors of PVD 5/8/2017
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF PERIPHERAL VASCULAR DISEASE Dr. Muhamad Zabidi Ahmad Radiologist and Section Chief, Radiology, Oncology and Nuclear Medicine Section, Advanced Medical and Dental
More informationLarry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationPeripheral Arterial Disease: Who has it and what to do about it?
Peripheral Arterial Disease: Who has it and what to do about it? Seth Krauss, M.D. Alaska Annual Nurse Practitioner Conference September 16, 2011 Scope of the Problem Incidence: 20%
More informationClinical Approach to CLI and Related Diagnostics: What You Need to Know
Clinical Approach to CLI and Related Diagnostics: What You Need to Know Ido Weinberg, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital None Disclosures Critical
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More informationStratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI?
Stratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI? Peter F. Lawrence, M.D. Gonda Vascular Center Division of Vascular Surgery
More informationPerfusion Assessment in Chronic Wounds
Perfusion Assessment in Chronic Wounds American Society of Podiatric Surgeons Surgical Conference September 22, 2018 Michael Maier, DPM, FACCWS Cardiovascular Medicine Cleveland Clinic Disclosures Speaker,
More informationGarland Green, MD Interventional Cardiologist. Impact of PAD: Prevalence, Risk Factors, Testing, and Medical Management
Garland Green, MD Interventional Cardiologist Impact of PAD: Prevalence, Risk Factors, Testing, and Medical Management Peripheral Arterial Disease Affects over 8 million Americans Affects 12% of the general
More informationLIMB SALVAGE IN THE DIABETIC PATIENT
LIMB SALVAGE IN THE DIABETIC PATIENT WHO? HOW? BEST? DISCLOSURES Educational grant from Cook Inc OBJECTIVES Review risk stratification and staging schemes for the threatened limb Discuss current concepts
More informationCase Report Successful Implantation of a Coronary Stent Graft in a Peripheral Vessel
Case Reports in Vascular Medicine Volume 2015, Article ID 725168, 4 pages http://dx.doi.org/10.1155/2015/725168 Case Report Successful Implantation of a Coronary Stent Graft in a Peripheral Vessel Alexander
More informationSAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS
SAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS LIBBY WATCH, MD MIAMI VASCULAR SPECIALISTS MIAMI CARDIAC & VASCULAR INSTITUTE FINANCIAL DISCLOSURES None 2
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationPeripheral Arterial Disease: the growing role of endovascular management
Peripheral Arterial Disease: the growing role of endovascular management Poster No.: C-1931 Congress: ECR 2012 Type: Educational Exhibit Authors: E. M. C. Guedes Pinto, E. Rosado, D. Penha, P. Cabral,
More informationAutologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results
ARTIcle Autologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results Min Li, 1 Hua Zhou, 2 Xing Jin, 2 Mo Wang, 2 Shiyi Zhang, 2 Lei Xu 2 Abstract
More informationObjective assessment of CLI patients Hemodynamic parameters
Objective assessment of CLI patients Hemodynamic parameters Worth anything in end stage patients? Marianne Brodmann Angiology, Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann
More informationVascular screening in diabetic patients: how aggressive should we be and when to intervene?
Vascular screening in diabetic patients: how aggressive should we be and when to intervene? Roberto Ferraresi Peripheral Interventional Unit Bergamo Italy Disclosure Speaker name: ROBERTO FERRARESI X X
More informationWhat s New in the Management of Peripheral Arterial Disease
What s New in the Management of Peripheral Arterial Disease Sibu P. Saha, MD, MBA Professor of Surgery Chairman, Directors Council Gill Heart Institute University of Kentucky Lexington, KY Disclosure My
More informationHybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case
Hybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case Chernyavskiy M.,MD,PhD, Chernova D., Zherdev N., Chernov A. Almazov National Medical Research Centre, St.Petersburg, Russia
More informationEvidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
More informationLower Extremity Peripheral Arterial Disease: Less is Sometimes More. Spence M Taylor, M.D.
Lower Extremity Peripheral Arterial Disease: Less is Sometimes More Spence M Taylor, M.D. President, Greenville Health System Clinical University Senior Associate Dean for Academic Affairs and Diversity
More informationEndovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial
Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial Prof. Thomas Zeller, MD Department Angiology Clinic for Cardiology and Angiology II University Heart-Center
More informationPAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler, MD September 14, 2016 Interventional Cardiology and Cath Labs Disclosures Research Grants: Agency for Healthcare Research
More informationImaging for Peripheral Vascular Disease
Imaging for Peripheral Vascular Disease James G. Jollis, MD Director, Rex Hospital Cardiovascular Imaging Imaging for Peripheral Vascular Disease 54 year old male with exertional calf pain in his right
More informationEasy. Not so Easy. Risk Assessment in the CLI Patient: Who is Likely to Benefit from Revascularization and Who is Not? 4/28/2012
Risk Assessment in the CLI Patient: Who is Likely to Benefit from Revascularization and Who is Not? Easy 89 yo Non-ambulatory Multiple failed interventions Forefoot and heel gangrene Andres Schanzer, MD
More informationMultidisciplinary approach to BTK Y. Gouëffic, MD, PhD
Multidisciplinary approach to BTK Y. Gouëffic, MD, PhD Department of vascular surgery, University Hospital of Nantes, France Response to the increased demand of hospital care Population is aging Diabetes
More informationBEST-CLI Trial Study Concept and Current Status
BEST-CLI Trial Study Concept and Current Status Kenneth Rosenfield, MD, MHCDS National Co-PI BEST-CLI Trial Section Head, Vascular Medicine and Intervention Institute for Heart, Vascular, and Stroke Care
More informationDisclosures. Critical Limb Ischemia. Vascular Testing in the CLI Patient. Vascular Testing in Critical Limb Ischemia UCSF Vascular Symposium
Disclosures Vascular Testing in the CLI Patient None 2015 UCSF Vascular Symposium Warren Gasper, MD Assistant Professor of Surgery UCSF Division of Vascular Surgery Critical Limb Ischemia Chronic Limb
More informationPedal Bypass With Deep Venous Arterialization:
Pedal Bypass With Deep Venous Arterialization: Long Term Result For Critical Limb Ischemia With Unreconstructable Distal Arteries Pramook Mutirangura Professor of Vascular Surgery Faculty of Medicine Siriraj
More information9 : , % % Tel : Tel : 5,6 7,8
9 : 491-497, 2000 1 1 2 1 1 1 1 1 73 5 60% 44% 11 25 55% 6 11 90% 9 10 10% 1 10 14% 1 7 9.7% 6 62 9.1% 5 55 29 30 10 33% 40% 4 10 100% 4 4 14 20 MNMS 1 2 1 III 1 2 4 1 9 : 491-497, 2000 1 Tel : 0764-24-1531
More informationIntroduction to Peripheral Arterial Disease. Stacey Clegg, MD Interventional Cardiology August
Introduction to Peripheral Arterial Disease Stacey Clegg, MD Interventional Cardiology August 20 2014 Outline (and for the ABIM board exam * ** ***) Prevalence* Definitions Lower Extremity: Aorta*** Claudication***
More informationPeripheral Arterial Disease Extremity
Peripheral Arterial Disease Lower Extremity 05 Contributor Dr Steven Chong Advisors Dr Ashish Anil Dr Tay Jam Chin Introduction Risk Factors Clinical Presentation Classification History PHYSICAL examination
More informationPeripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment
Peripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment Prepared and Presented by Jon Manocchio, Pharm D Blanchard Valley Hospital October 2011 Introduction PAD is a condition that is
More information2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationInterventional Treatment First for CLI
Interventional Treatment First for CLI Patrick Alexander, MD, FACC, FSCAI Interventional Cardiology Medical Director, Critical Limb Clinic Providence Heart Institute, Southfield MI 48075 Disclosures Consultant
More informationPeripheral arterial disease for primary care Ed Aboian, MD
Peripheral arterial disease for primary care Ed Aboian, MD Division of Vascular and Endovascular Surgery Palo Alto Medical Foundation, Burlingame Ca Disclosures Nothing to disclose Clinical presentation
More informationLower Extremity Artery: Physiologic Testing
Master Title Ultrasound for Initial Evaluation of Lower Extremity Arterial Occlusive Disease: WHY? Gregory L. Moneta MD Professor and Chief Knight Cardiovascular Institute Division of Vascular Surgery
More informationIntercepting PAD. Playbook for Cardiovascular Care 2018 February 24, Jonathan D Woody, MD, FACS. University Surgical Vascular
Intercepting PAD Playbook for Cardiovascular Care 2018 February 24, 2018 Jonathan D Woody, MD, FACS University Surgical Vascular Attending Vascular Surgeon - Piedmont Athens Regional Adjunct Clinical Associate
More informationNurse and Technician Forum Part II Critical Limb Ischemia: Optimal care, an interdisciplinary challenge
L E I P Z I G I N T E R V E N T I O N A L C O U R S E 2017 Nurse and Technician Forum Part II Critical Limb Ischemia: Optimal care, an interdisciplinary challenge Markus Haumer Landesklinikum Baden-Mödling
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 6/30/2012 Radiology Quiz of the Week # 79 Page 1 CLINICAL PRESENTATION AND RADIOLOGY
More informationGLOBAL VASCULAR GUIDELINES: A NEW PATHWAY FOR LIMB SALVAGE
GLOBAL VASCULAR GUIDELINES: A NEW PATHWAY FOR LIMB SALVAGE Michael S. Conte MD Professor and Chief, Vascular and Endovascular Surgery Co-Director, Center for Limb Preservation Co-Director, Heart and Vascular
More informationHistory & Literature Review
History & Literature Review History In the earliest stages of research, ACI Medical observed significant increases in arterial blood flow while testing a device that applied rapid, high level compressions
More informationNovel distal popliteal artery puncture technique in supine position for chronic femoropopliteal arterial occlusion; frontal popliteal puncture
Novel distal popliteal artery puncture technique in supine position for chronic femoropopliteal arterial occlusion; frontal popliteal puncture Miyazaki Medical Association Hospital Cardiovascular Center
More informationGuidelines for Management of Peripheral Arterial Disease
Guidelines for Management of Peripheral Arterial Disease Subhash Banerjee, MD, FACC, FSCAI Professor of Medicine, Univ. of Texas Southwestern Medical Center Chief, Division of Cardiology, VA North Texas
More informationThe results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan
The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan COI disclosure Disclosure Speaker name: Taku Kato... I have the
More informationEndovascular Should Be Considered First Line Therapy
Revascularization of Patients with Critical Limb Ischemia Endovascular Should Be Considered First Line Therapy Michael Conte David Dawson David L. Dawson, MD Revised Presentation Title A Selective Approach
More informationWifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization
Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization A Sonetto, M Abualhin, M Gargiulo, GL Faggioli, A Stella Disclosure Speaker
More informationMedical Therapy for Peripheral Artery Disease
Medical Therapy for Peripheral Artery Disease Beau M. Hawkins, MD, FSCAI University of Oklahoma Health Sciences Center, Oklahoma City, OK Sahil A. Parikh, MD, FSCAI Columbia University Medical Center,
More informationDisclosures. Tips and Tricks for Tibial Intervention. Tibial intervention overview
Tips and Tricks for Tibial Intervention Donald L. Jacobs, MD C Rollins Hanlon Endowed Professor and Chair Chair of Surgery Saint Louis University SSM-STL Saint Louis University Hospital Disclosures Abbott
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report G. Biro, M. Bosiers on behalf of ZILVERPASS Study Group Disclosure Speaker
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ABI. See Ankle-brachial index (ABI). Afterload, deconstructing of, in ventricular vascular interaction in heart failure, 449 Air plethysmography
More informationNational Clinical Conference 2018 Baltimore, MD
National Clinical Conference 2018 Baltimore, MD No relevant financial relationships to disclose Wound Care Referral The patient has been maximized from a vascular standpoint. She has no other options.
More informationThe incidence of peripheral artery disease (PAD)
Pharmacologic Options for Treating Restenosis The role of cilostazol in the treatment of patients with infrainguinal lesions. By Osamu Iida, MD, and Yoshimitsu Soga, MD The incidence of peripheral artery
More informationUC SF. Disclosures. Vascular Assessment of the Diabetic Foot. What are the best predictors of wound healing? None. Non-Invasive Vascular Studies
Disclosures Vascular Assessment of the Diabetic Foot What are the best predictors of wound healing? None Shant Vartanian MD Assistant Professor of Vascular Surgery UCSF Vascular Symposium April 20, 2013
More informationPeripheral Vascular Disease
Peripheral artery disease (PAD) results from the buildup of plaque (atherosclerosis) in the arteries of the legs. For people with PAD, symptoms may be mild, requiring no treatment except modification of
More informationDisclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are
An initial strategy of open bypass is better for some CLI patients, and we can define who they are Fadi Saab, MD, FASE, FACC, FSCAI Metro Heart & Vascular Metro Health Hospital, Wyoming, MI Assistant Clinical
More informationLimb Salvage in Diabetic Ischemic Foot. Kritaya Kritayakirana, MD, FACS Assistant Professor Chulalongkorn University April 30, 2017
Limb Salvage in Diabetic Ischemic Foot Kritaya Kritayakirana, MD, FACS Assistant Professor Chulalongkorn University April 30, 2017 Case Male 67 years old Underlying DM, HTN, TVD Present with gangrene
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationNational Vascular Registry
National Vascular Registry Angioplasty Patient Details Patient Consent* 2 Not Required If patient not consented: Date consent recorded / / (DD/MM/YYYY) Do not record NHS number, NHS number* name(s) or
More informationObjectives. Abdominal Aortic Aneuryms 11/16/2017. The Vascular Patient: Diagnosis and Conservative Treatment
The Vascular Patient: Diagnosis and Conservative Treatment Ferrell-Duncan Clinic Zachary C. Schmittling, M.D., F.A.C.S. Vascular and General Surgery Ferrell-Duncan Clinic Cox Health Systems Objectives
More informationClinical and social consequences of Buerger disease
Clinical and social consequences of Buerger disease Takashi Ohta, MD, Hiroyuki Ishioashi, MD, Minoru Hosaka, MD, and Ikuo Sugimoto, MD, Aichi, Japan Purpose: This study was undertaken to assess the clinical
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]
More informationThe Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology
The Crack and Pave technique for highly resistant calcified lesions Manuela Matschuck MD University Hospital Leipzig Department Angiology Disclosure Speaker name: Dr. med. Manuela Matschuck I have the
More informationRevascularisation for Claudication: When is it indicated, when not? Markus Haumer Landesklinikum Baden-Mödling Austria
Revascularisation for Claudication: When is it indicated, when not? Markus Haumer Landesklinikum Baden-Mödling Austria Disclosure Disclosure Speaker name: Markus Haumer, MD I have the following potential
More informationAbstract. Key words: peripheral artery disease, lower limb, endovascular therapy, Iran
The evaluation of the success rate, complications and midterm follow up results of patients with peripheral arterial disease of lower limb treated using endovascular therapy: A single center study Mohammad
More informationAngiosome revascularization strategies in real world practice: how much difference does it make?
Angiosome revascularization strategies in real world practice: how much difference does it make? Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii Disclosure Peter A. Schneider... I have
More informationOptimization of Generx (Ad5FGF-4) Clinical Trial Design for Refractory Angina: Interim Results of the Phase 3 ASPIRE Trial
Optimization of Generx (Ad5FGF-4) Clinical Trial Design for Refractory Angina: Interim Results of the Phase 3 ASPIRE Trial Gabor M Rubanyi, MD. PhD. Angionetics Inc., San Diego, CA ASGCT, New Orleans,
More informationGoals of Screening Programs. What is Vascular Screening? Assumptions Regarding the Potential Benefits of Screening Programs PAD
Conflict of Interest Disclosure (Relationships with Industry) An Epidemic of : The Debate Over Population Screening Membership on an advisory board, consultant, or recipient of a research grant from the
More informationFrom the Society for Vascular Surgery
From the Society for Vascular Surgery Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity
More informationHybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results.
Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results. Wronski J. 1), 2) 3), Wilczynski M 1), Gembal P 1), Milik K 1), Dec St 1), Grybos
More informationV.A. is a 62-year-old male who presents in referral
, LLC an HMP Communications Holdings Company Clinical Case Update Latest Trends in Critical Limb Ischemia Imaging Amit Srivastava, MD, FACC, FABVM Interventional Cardiologist Bay Area Heart Center St.
More informationPeripheral Artery Disease Role of Exercise, Endovascular and Surgical Options
Peripheral Artery Disease Role of Exercise, Endovascular and Surgical Options Jeffrey W. Olin, D.O., F.A.C.C., F.A.H.A. Professor of Medicine (Cardiology) Director of Vascular Medicine & the Vascular Diagnostic
More informationNew Data to Shape the Era of Drug Elution in Peripheral Interventions
New Data to Shape the Era of Drug Elution in Peripheral Interventions William A. Gray MD Director of Endovascular Services Columbia University Medical Center New York Lower Extremity Endovascular - Interventions
More informationPeripheral Arterial Disease. Westley Smith MD Vascular Fellow
Peripheral Arterial Disease Westley Smith MD Vascular Fellow Background (per 10,000) Goodney P, et al. Regional intensity of vascular care and lower extremity amputation rates. JVS. 2013; 6: 1471-1480.
More informationI have no financial disclosures
Manpreet Singh MD I have no financial disclosures Exercise Treadmill Bicycle Functional capacity assessment Well validated prognostic value Ischemic assessment ECG changes ST segments Arrhythmias Hemodynamic
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationAbdominal Aortic Doppler Waveform in Patients with Aorto-iliac Disease
Eur J Vasc Endovasc Surg (2010) 39, 714e718 Abdominal Aortic Doppler Waveform in Patients with Aorto-iliac Disease G. Styczynski a, *, C. Szmigielski a, J. Leszczynski b, A. Kuch-Wocial a, M. Szulc a a
More informationLIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:
LIBERTY 360 Study LIBERTY is a prospective, observational, multi-center study to evaluate procedural and long-term clinical and economic outcomes of endovascular device interventions in patients with symptomatic
More informationCase Discussion. Disclosures. Critical Limb Ischemia: A Selective Approach to Revascularization Works Best 4/28/2012. None. 58 yo M, DM, CAD, HTN
Critical Limb Ischemia: A Selective Approach to Revascularization Works Best None Disclosures Michael S. Conte MD, FACS Division of Vascular and Endovascular Surgery Co-Director, Heart and Vascular Center
More information